The clearance was based on the 20-patient Rapid trial, a prospective, single-arm, single-center study designed to look at the safety and effectiveness of the CorPath device in peripheral artery disease patients with lower-extremity blockages.
“For the past 2 years, I have been successfully treating my coronary patients with robotic precision while protecting my staff and me from the hazards of radiation exposure in the cath lab,” co-lead investigator Dr. Ehtisham Mahmud, of the UC San Diego Health System, said in prepared remarks. “The ability to expand robotic precision to treat my peripheral disease patients is an important addition; I am looking forward to continued work with Corindus to optimize robotic therapy for peripheral procedures.”
“Our first priority is to provide the best care to our patient community via robotic precision while protecting the physicians performing these important procedures,” added new president & CEO Mark Toland. “This FDA clearance demonstrates our commitment to the development of clinical data in our endeavor to expand the scope of robotic therapy.”
The partnership will allow cath lab physicians and staff to better monitor and protect themselves from excessive radiation exposure, Waltham, Mass.-based Corindus said.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.